Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

ClinicalTrials.gov ID: NCT03164967

Public ClinicalTrials.gov record NCT03164967. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16

Study identification

NCT ID
NCT03164967
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
ADMA Biologics, Inc.
Industry
Enrollment
16 participants

Conditions and interventions

Interventions

  • Bivigam Biological

Biological

Eligibility (public fields only)

Age range
2 Years to 16 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2016
Primary completion
Aug 29, 2022
Completion
Dec 30, 2022
Last update posted
Jan 31, 2023

2016 – 2022

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
IMMUNOe Research Centers Centennial Colorado 80112
Duke University Medical Center Durham Florida 27710
Allergy Associates of the Palm Beaches North Palm Beach Florida 33408
USF Health, Pediatric Allergy, Immunology & Rheumatology St. Petersburg Florida 33701
Ohio Clinical Research Associates Mayfield Heights Ohio 44124
Oklahoma Institute of Allergy and Asthma Clinical Research Oklahoma City Oklahoma 73131
Discovery Clinical Trials Dallas Texas 75225
Lysosomal Rare Disorders Research & Treatment Center Fairfax Virginia 22030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03164967, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2023 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03164967 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →